3.59  -0.22 (-5.77%)		11-06 16:00
Open: 3.81 High: 3.81 Volume: 2,932,738		Pre. Close: 3.81 Low: 3.545 Market Cap: 537(M)

Short term
Mid term
Targets	6-month :	5.24	1-year :	6.1
Resists	First :	4.48	Second :	5.22
Pivot price	4.25
Supports	First :	3.28	Second :	2.73
MAs	MA(5) :	3.94	MA(20) :	4.24
	MA(100) :	3.12	MA(250) :	3.2
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	5.1	D(3) :	17.2
RSI	RSI(14): 42.8
52-week	High :	6.32	Low :	2

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABSI ] has closed below the lower bollinger band by 5.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ABSI ] is to continue within current trading range. Bollinger Bands are 28% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.94 - 3.98	3.98 - 4
Low:	3.64 - 3.67	3.67 - 3.7
Close:	3.76 - 3.82	3.82 - 3.85

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Wed, 05 Nov 2025
Vanguard Group Inc's Strategic Acquisition of Absci Corp Shares - GuruFocus

Wed, 05 Nov 2025
Absci Finalizes Milestone Distribution Agreement with SBGH - MSN

Wed, 05 Nov 2025
Absci (ABSI) Expected to Announce Earnings on Wednesday - MarketBeat

Tue, 04 Nov 2025
Absci Finalizes Milestone Distribution Agreement with SBGH - TipRanks

Wed, 15 Oct 2025
Absci climbs on clinical trial acceleration (ABSI:NASDAQ) - Seeking Alpha

Mon, 13 Oct 2025
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	150 (M)
Held by Insiders	1.3193e+008 (%)
Held by Institutions	9.3 (%)
Shares Short	33,150 (K)
Shares Short P.Month	0 (K)

EPS	-1.0373e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	293.9 %
Return on Equity (ttm)	-31.3 %
Qtrly Rev. Growth	4.14e+006 %
Gross Profit (p.s.)	-25.63
Sales Per Share	-27.59
EBITDA (p.s.)	-3.2524e+007
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-76 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.13
Price to Cash Flow	5.48

Dividend	0
Forward Dividend	3.106e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.